Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
68 hedge funds and large institutions have $65.7M invested in Vincerx Pharma, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 4 closing their positions.
325% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 4
24% more funds holding
Funds holding: 55 → 68 (+13)
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
4.73% more ownership
Funds ownership: 73.22% → 77.96% (+4.7%)
58% less capital invested
Capital invested by funds: $157M → $65.7M (-$91.1M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$3.22M |
| 2 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$1.79M |
| 3 |
CC
Clearline Capital
New York
|
+$1.74M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$1.47M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$7.55M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.02M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$241K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$170K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$149K |
VINC Hedge Fund Activity: Q1 2022 in Review
68 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q1 2022, worth a combined $65.7M — down 58% from $157M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new VINC positions and 4 closed out — a net gain of 13 holders — while 18 added to existing stakes and 15 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $3.22M. The largest seller was RTW Investments, exiting entirely with an estimated $7.55M sold.
- 68 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q1 2022, up from 55 in Q4 2021.
- Funds reported $65.7M of Vincerx Pharma, Inc. Common Stock stock for Q1 2022, down 58% quarter-over-quarter.
- 17 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q1 2022 and 4 closed out, a net change of +13 holders.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q1 2022 was Rubric Capital Management (New York), an estimated $3.22M added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q1 2022 was RTW Investments, an estimated $7.55M sold.
Based on aggregated 13F filings for Q1 2022.